These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Høilund-Carlsen PF; Alavi A J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891 [TBL] [Abstract][Full Text] [Related]
10. Aducanumab: The first targeted Alzheimer's therapy. Yang P; Sun F Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067 [TBL] [Abstract][Full Text] [Related]
11. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243 [TBL] [Abstract][Full Text] [Related]
12. Aducanumab for the treatment of Alzheimer's disease. Tagliapietra M Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541 [TBL] [Abstract][Full Text] [Related]
13. Making the Case for Accelerated Withdrawal of Aducanumab. Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287 [TBL] [Abstract][Full Text] [Related]
14. Aducanumab (Aduhelm) for Alzheimer's disease. Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258 [No Abstract] [Full Text] [Related]
15. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis? Silvestro S; Valeri A; Mazzon E Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126 [TBL] [Abstract][Full Text] [Related]
16. A Bayesian perspective on Biogen's aducanumab trial. Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700 [TBL] [Abstract][Full Text] [Related]
17. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid. Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320 [TBL] [Abstract][Full Text] [Related]
19. Can we learn lessons from the FDA's approval of aducanumab? Liu KY; Howard R Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787 [TBL] [Abstract][Full Text] [Related]
20. Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Gandy S; Knopman DS; Sano M Mol Neurodegener; 2021 Nov; 16(1):74. PubMed ID: 34736482 [No Abstract] [Full Text] [Related] [Next] [New Search]